Photo credits
_40mg_Capsule.jpg){kind=link}
Why Atomoxetine Matters
Atomoxetine is the first drug the FDA ever approved specifically for adult ADHD, and it remains the prototype non-stimulant. Its selling point has held up: it treats ADHD without being a controlled substance. No DEA paperwork, no monthly-visit requirement to generate a new prescription, no diversion, no abuse potential, no "my script got stolen" phone calls. You can send refills like you would for an SSRI. For a large slice of patients (those with substance use histories, those you can't see monthly, those who don't want a stimulant, those for whom stimulants failed or can't be used), that alone earns it a place in your toolkit.
Atomoxetine is not as effective as a stimulant, and it isn't close. In head-to-head trials, stimulants post effect sizes of 0.8–0.9 and numbers-needed-to-treat of 2–4; atomoxetine lands at effect size 0.4–0.6 and NNT 5–7. In the largest pediatric head-to-head (Newcorn 2008, n=516), Concerta produced a 56% response rate versus atomoxetine's 45% versus placebo's 24%. It works, it clearly beats placebo, but it is a second- or third-line agent for garden-variety ADHD.
It also asks for patience, which is the single biggest adjustment for a prescriber coming from stimulants. Where a stimulant works in an hour and you know by the end of the day whether the dose was right, atomoxetine builds slowly: some symptom improvement within about two weeks, but full benefit taking up to 10 weeks. Give it a 4–6 week trial at an adequate dose before you judge it. Patients (and prescribers) who expect stimulant-like immediacy will quit it prematurely and wrongly conclude it "doesn't work."
Atomoxetine is a solid, non-abusable, once-daily ADHD drug whose success depends almost entirely on dose, patience and one pathway: dosing it high enough (to a milligram-per-kilogram target, not a timid fixed dose), giving it long enough (weeks, not days), and respecting its one pharmacokinetic landmine, CYP2D6. Do those three things and it delivers. Skip any of them and it looks like a failure that isn't the drug's fault.
Part 1: Indications
FDA-Approved Uses
- ADHD in children age ≥6 and in adults: monotherapy, or as an adjunct to a stimulant.
That is the entire FDA label. Atomoxetine was originally developed as an antidepressant and failed; it found its second life in ADHD, where it became, in 2002, one of the first new ADHD mechanisms in decades.
Where Atomoxetine Earns Its Keep
It is at its best in a handful of specific clinical situations:
ADHD + substance use disorder
Because atomoxetine increases dopamine in the prefrontal cortex but not in the striatum, it has no reinforcing/euphoric effect and no abuse potential. It is unscheduled. For a patient with active or historical addiction, where handing over a bottle of amphetamine is fraught, atomoxetine is arguably the single best ADHD choice available. This is a case where atomoxetine may be your first choice rather than a fallback.
ADHD + anxiety
Stimulants can wind anxious patients tighter. Atomoxetine tends not to, and there's real (if industry-sponsored) evidence it helps. A 14-week RCT in adults (Adler 2009, n=442) found atomoxetine beat placebo on both ADHD symptoms (p<0.001) and social anxiety (p<0.001). It's a reasonable pick for the ADHD patient whose comorbid anxiety you'd rather not aggravate.
When a controlled substance is undesirable or impractical
Patients who don't want a stimulant, adolescents in households where diversion is a concern, patients you can only see infrequently, athletes or professionals subject to drug testing, or anyone for whom the controlled-substance logistics are a barrier.
When stimulants failed or aren't tolerated
Insomnia, appetite suppression, tics, rebound irritability, cardiovascular jitteriness: atomoxetine sidesteps several of these and is worth a try when stimulants can't be optimized.
Some patients respond preferentially to atomoxetine even though the average patient does better on a stimulant. A modest average effect size hides real individual variation. A stimulant "failure" is not an atomoxetine failure, and vice versa. If a well-conducted atomoxetine trial disappoints, the answer is usually a stimulant, not another non-stimulant.
Off-Label Uses With Some Evidence
Real signals, mostly from small trials, useful when the comorbidity sits alongside ADHD and rarely worth chasing on their own:
- Binge eating disorder: 10-week RCT (n=40) reduced binge frequency (p=0.034) and weight (p=0.018).
- Obesity: 12-week RCT (n=20) reduced weight (p<0.0001).
- Obstructive sleep apnea: atomoxetine combined with oxybutynin at bedtime cut the apnea-hypopnea index in a placebo-controlled crossover trial, with every patient in the polysomnography subgroup dropping at least 50%, while either agent given alone did not. The combination is what is in development, so this is not a reason to pick atomoxetine on its own.
Where NOT to Use It
- Depression. Despite being born as an antidepressant, atomoxetine failed rigorous double-blind trials. If your patient has ADHD + depression, bupropion is the more sensible reach, since it is approved for depression and has modest ADHD evidence of its own.
- Bipolar disorder. This caution is not a formality. Atomoxetine is noradrenergic, and noradrenergic agents (think venlafaxine, tricyclics) carry the highest risk of flipping patients into mania. Its exact switch rate is unknown, but there are case reports of mania and psychosis. In a patient with bipolar ADHD, the alpha-2 agonists (guanfacine, clonidine) are far safer choices.
The two drugs atomoxetine's own history most resembles are both pure norepinephrine reuptake inhibitors: the obsolete tricyclic maprotiline and the European antidepressant reboxetine. Keep that lineage in mind: in its mania risk and its cardiovascular profile, atomoxetine behaves more like a noradrenergic antidepressant than like a stimulant.
Part 2: Workup and Candidacy
Atomoxetine requires far less pre-start machinery than lithium or a stimulant workup, but a few things are non-negotiable.
Baseline Assessment
| Item | Why |
|---|---|
| Heart rate and blood pressure | Atomoxetine raises both (like a stimulant). Establish a baseline you can track. |
| Cardiac history / exam | Screen for structural heart disease, arrhythmia, uncontrolled hypertension. |
| Medication reconciliation for CYP2D6 inhibitors | Fluoxetine, paroxetine, bupropion: these lengthen the titration interval (see Part 7). |
| Screen for bipolar disorder | Noradrenergic mechanism = mania risk. Don't miss an underlying bipolar diathesis. |
| Hepatic history | Metabolized in the liver; caution in hepatic disease. |
- Baseline ECG is NOT routinely required. Atomoxetine can rarely prolong QTc, but the FDA does not recommend a routine baseline ECG. Get one if there's pre-existing cardiac disease, syncope, a concerning family history, or you're in an older/frailer patient.
- CYP2D6 genotyping is optional. The FDA leaves it to clinician judgment and does not recommend routine testing. It's most useful when you already suspect poor metabolism (severe side effects at low doses) or when you're stacking atomoxetine on a strong 2D6 inhibitor.
Who Is a Poor Candidate?
- Severe cardiac or vascular disease whose condition would be expected to deteriorate with a clinically important rise in blood pressure or heart rate: contraindicated by the label. The label's other contraindications are an MAOI now or within 14 days, narrow-angle glaucoma, pheochromocytoma (current or past), and hypersensitivity to atomoxetine.
- Bipolar disorder (relative; high mania-induction concern).
- Narrow-angle glaucoma: contraindicated; the label cites an increased risk of mydriasis.
- Seizure disorder: caution (lowers threshold in theory).
- Tics: caution; monitor if pre-existing.
- Significant hepatic impairment: caution; dose-reduce.
- Patients who need a fast answer: if someone needs symptom control in days, not weeks, this is the wrong drug.
Part 3: How to Start and Dose
Liver impairment (ages 6 and older)ADHDFDA labelModerate (Child-Pugh B): 50% of the initial and target dose. Severe (Child-Pugh C): 25%. Mild (Child-Pugh A): same as normal.
Strong 2D6 inhibitor or poor metabolizerADHDFDA labelSame doses as the standard table. A 4-week titration interval is recommended if ADHD symptoms fail to improve and the initial dose is well tolerated.
Timing, food and missed dosesADHDFDA labelOnce daily in the morning, or evenly divided twice daily (morning and late afternoon or early evening). May be taken with or without food.In practiceOnce daily is usually enough. Split twice daily for stomach upset or when coverage fades. For stomach upset, take with food.
Stopping, and MAOI switchesADHDFDA labelNo taper needed. At least 14 days between stopping an MAOI and starting atomoxetine, and between stopping atomoxetine and starting an MAOI.In practiceA brief taper is still reasonable, to watch for return of ADHD symptoms and any mood change.
Formulation
Atomoxetine comes as capsules (available generic since 2017, so cost is no longer a barrier). The label is explicit that the capsules are not intended to be opened and should be taken whole, so there is no sprinkle option for a child or an adult who can't swallow one. The powder inside is an ocular irritant: wash hands after handling a capsule that has come apart, and flush the eye with water if any gets in.
Despite a short half-life (about 5 hours in most patients), atomoxetine can be dosed once or twice daily. Once daily is simplest and usually sufficient; twice daily (morning and late afternoon) is a lever you can pull for GI intolerance or for patients who feel coverage fade.
Atomoxetine is dose-dependent, and 40 mg is a starting dose, not a treatment dose. Patients parked at 40 mg who "didn't respond" frequently just never got to a therapeutic level. Get to ~1.2 mg/kg (or 80–100 mg in an adult) before you call it a failure.
The Two Rules That Determine Success
- Dose it high enough. See above. Target the milligram-per-kilogram number, not a comfortable low fixed dose.
- Give it long enough. Set expectations on day one: "You may notice something in two weeks, but this drug keeps building for up to ten weeks. We won't judge it until you've had a solid four to six weeks at a full dose." This is the counseling that prevents premature discontinuation, the number-one reason atomoxetine "fails."
The CYP2D6 Dose Modification (Critical)
If your patient is a known CYP2D6 poor metabolizer (~2–10% of the population) or is taking a strong CYP2D6 inhibitor (fluoxetine, paroxetine, or bupropion):
- Start at the usual starting dose (40 mg/day for adults and for children weighing 70 kg or more; 0.5 mg/kg/day for lighter children).
- Wait at least 4 weeks before increasing (the usual minimum is 3 days), and only if ADHD symptoms have not improved and the starting dose is well tolerated.
- The target and maximum doses stay the same. The label keeps them unchanged and does not call for a lower target.
In poor metabolizers, atomoxetine peak levels run roughly 5-fold higher (AUC about 10-fold), and these patients are about twice as likely to discontinue for side effects. This is the closest thing atomoxetine has to a narrow-therapeutic-window problem, and it's entirely manageable if you check the med list before you write.
Dose Adjustments and Special Populations
- Boxed warning: increased risk of suicidal ideation in children and adolescents. Monitor closely, especially early and after dose changes.
- Cardiovascular: avoid in known structural cardiac disease or serious arrhythmia; check baseline and on-treatment BP and heart rate (atomoxetine raises both modestly).
- MAOI: contraindicated within 14 days of an MAOI.
- Pregnancy: limited data; use only if clearly needed. Stopping: no taper strictly required (no dependence), but symptoms return on discontinuation.
Part 4: Monitoring
Atomoxetine has no serum level to chase and no routine bloodwork mandate. Monitoring is clinical and cardiovascular.
| Timepoint | Check |
|---|---|
| Baseline | HR, BP, cardiac screen |
| Every dose increase | HR, BP |
| Periodically once stable | HR, BP (FDA recommends periodic vital-sign checks) |
| Ongoing | ADHD symptom response; emergence of suicidal ideation (esp. children/adolescents, first weeks); mania/agitation |
- No routine labs, no routine ECG, no drug levels.
- Recheck an ECG only if new palpitations, syncope, or you've stacked another QTc-affecting drug.
- In children and adolescents, monitor for suicidal ideation the way you would when starting an antidepressant, more closely in the first few weeks and after dose changes.
- Watch everyone for mania, psychosis, aggression or hostility, not only those with a bipolar diathesis; the label notes they can appear with no prior history.
The response timeline is the monitoring plan. Because full effect takes up to 10 weeks, book a follow-up at ~4–6 weeks (to confirm you're at an adequate dose and check vitals) and again at ~10–12 weeks (to make the keep-or-switch call). Week 2 is too early to judge the response.
Part 5: Side Effects and How to Manage Them
Most atomoxetine side effects are dose-related, worst during titration, and improve with time. So titrate slowly enough that the patient stays on the drug long enough for it to work.
Gastrointestinal (Nausea, Upset Stomach)
Common, especially early.
Management:
- Take with food: the simplest and most effective fix.
- Split to twice daily to lower peak concentration.
- Slow the titration; most GI upset settles within a couple of weeks.
Fatigue and Somnolence
This is atomoxetine's most distinctive tolerability problem and the mirror image of stimulants (which cause insomnia). Roughly 1 in 20 patients (5%) get severe fatigue. It can be disabling.
Management:
- Move the dose to the evening if daytime somnolence dominates, since the short half-life means much of the sedation can be slept off.
- Conversely, if it causes insomnia (it can go either way), dose in the morning. Let the side-effect direction pick the timing.
- Take with food.
- If fatigue is severe and persistent, it may simply be the wrong drug for this patient, so don't force it.
Appetite and Weight
Appetite suppression occurs but is less than with stimulants. Some modest weight loss in kids; usually self-limited. Track growth in children as you would on any ADHD drug.
Cardiovascular
Atomoxetine raises heart rate and blood pressure modestly, just like a stimulant, via its noradrenergic action.
Management:
- Recheck HR/BP at each dose step and periodically.
- If BP or HR climbs meaningfully, reduce the dose or reconsider the drug; coordinate with the PCP if the patient is on antihypertensives.
- Rare QTc prolongation exists but does not warrant routine ECG screening.
Psychiatric / CNS
- Suicidal ideation: carries an antidepressant-style warning in children and adolescents (see the boxed warning in Part 6). Case reports exist; it was not statistically significant in controlled trials. Monitor early, as with any antidepressant start in youth.
- Mania / psychosis: rare. The label (5.5) says psychotic or manic symptoms can occur at usual doses in people with no prior psychosis or mania, so screen for bipolar disorder first but watch everyone. If they appear, consider stopping.
- Aggression or hostility: the label asks you to monitor for new or worsening aggressive behavior or hostility after starting.
- Irritability, mood lability: occasional; usually dose-related.
Genitourinary / Sexual (Adults)
Noradrenergic tone can cause urinary hesitancy/retention and sexual dysfunction (and, uncommonly, priapism; counsel patients to seek urgent care for a prolonged erection). These are worth asking about directly, since patients rarely volunteer them.
Hepatic (Rare but Important)
Rare cases of hepatotoxicity have been reported (elevated transaminases, jaundice, occasionally severe). This is not common enough to justify routine LFT monitoring, but counsel patients to report dark urine, jaundice, right-upper-quadrant pain, or unexplained flu-like malaise, and check LFTs and stop the drug if they do.
Part 6: Overdose, Toxicity, and Warnings
Atomoxetine has no narrow therapeutic window in the lithium sense, and overdose does not produce a classic toxicity syndrome. It does carry a boxed warning, for suicidal ideation in children and adolescents, and its safety profile is closer to an antidepressant's than a stimulant's.
The Boxed Warning
Atomoxetine carries the antidepressant-class boxed warning for increased suicidal ideation in children and adolescents, a warning the stimulants do not carry. Monitor closely at initiation and after every dose change, particularly in the first few weeks of treatment.
Other Warnings
- Rare sudden death: the label reports sudden death at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems, and sudden death, stroke and myocardial infarction in adults. Severe cardiac or vascular disorders that a rise in blood pressure or heart rate would worsen are a contraindication, and you screen the heart before starting.
- Hepatotoxicity: rare, idiosyncratic; stop for any sign of liver injury.
Overdose
Overdose experience is limited and generally less lethal than with stimulants or tricyclics. Expected features reflect exaggerated noradrenergic effect: tachycardia, hypertension, agitation, somnolence, GI upset, and occasionally seizures or QTc changes. Management is supportive; there is no specific antidote, and because atomoxetine is highly protein-bound, dialysis is not useful. Any significant overdose is an ED evaluation with cardiac and neurologic observation.
The relatively benign overdose profile is an advantage in the impulsive or self-harming patient for whom you'd hesitate to hand over a lethal-in-overdose medication. It's one more reason atomoxetine fits the anxious, comorbid, or higher-risk patient who also can't have a controlled stimulant.
Part 7: Drug Interactions and CYP2D6
Atomoxetine is metabolized almost entirely through one hepatic pathway: CYP2D6. Touch that pathway and its levels swing hard. Interactions at that one pathway dominate its prescribing; everything else is minor.
Strong CYP2D6 Inhibitors (Raise Atomoxetine Levels)
Co-prescribing any of these turns your patient, pharmacologically, into a poor metabolizer:
- Fluoxetine
- Paroxetine
- Bupropion
Action (from the label): keep the usual starting dose, wait at least 4 weeks before the first increase (and only if symptoms have not improved and the start dose is tolerated), and keep the usual target and maximum. These are common psychiatric co-meds; an ADHD patient on fluoxetine or bupropion is an everyday scenario. Check the list every time.
Duloxetine is not on this list. It is a moderate 2D6 inhibitor, and in one small study in healthy volunteers given a single atomoxetine dose it raised atomoxetine exposure by about 30%, against 6.5-fold with paroxetine and 6- to 8-fold with fluoxetine in the Strattera label. The label's slower-titration rule is written for strong inhibitors.
Two of the most common antidepressants a psychiatrist reaches for (fluoxetine, bupropion) are strong 2D6 inhibitors, and bupropion is itself sometimes used for ADHD. If you're layering atomoxetine onto either, use the 4-week titration interval the label calls for, otherwise you'll manufacture a "poor metabolizer" and blame the drug for the side effects you caused.
CYP2D6 Poor Metabolizers (Genetic)
Same clinical picture without any inhibitor: ~5-fold higher peaks, twice the discontinuation rate. Same label dosing rule (usual start, 4-week titration interval, usual target and maximum). Genotyping is optional but can explain a patient who can't tolerate even small doses.
Combinations to Avoid or Approach Cautiously
- Atomoxetine + stimulant: safety "not fully established." Some reports support it, but if you need to augment, guanfacine has actual controlled-trial evidence for augmenting stimulants with fewer cardiovascular concerns. Prefer the alpha-2 agonist.
- MAOIs, linezolid and intravenous methylene blue: contraindicated. The label counts linezolid and IV methylene blue as MAOIs, and also bars atomoxetine within 14 days of stopping an MAOI.
- Albuterol and other beta-2 agonists: systemic albuterol (for example oral) is potentiated by atomoxetine, with higher heart rate and blood pressure. Monitor both more often.
- Blood-pressure medicines and pressor drugs (dopamine, dobutamine): use cautiously, monitor blood pressure more often and adjust as needed.
- Other noradrenergic/pressor agents can compound hypertension and mania risk.
Part 8: Special Populations
Pregnancy
Human safety data are limited; risk is not well established. There is no signal as alarming as valproate's, but there's also not enough data to call it safe. Weigh the severity of ADHD against the uncertainty (many patients can pause ADHD pharmacotherapy through pregnancy) and make an individualized, documented decision, ideally with maternal-fetal input.
Lactation
Safety unknown; atomoxetine is expected to enter breast milk. If used, monitor the infant for sedation, poor feeding, and irritability, and involve pediatrics.
Children and Adolescents (≥6 years)
- Approved from age 6. Dose by weight (0.5 mg/kg start → ~1.2 mg/kg target, max 1.4 mg/kg or 100 mg, whichever is less).
- Effect size 0.4–0.6.
- Suicidal ideation warning applies: monitor early.
- Track growth and vitals.
Adults
Approved and effective, effect size ~0.45. Same CYP2D6 cautions. The adult ADHD patient with anxiety, a substance-use history, or an aversion to controlled substances is the classic adult atomoxetine candidate.
Elderly
Little specific data. Use extra caution for the cardiovascular effects (HR/BP), consider a baseline ECG in the frail, start low, and reconcile the (often long) medication list for 2D6 inhibitors.
Hepatic Impairment
Because clearance is hepatic, reduce the dose in hepatic impairment (moderate impairment generally warrants ~50% reduction; severe, ~75%). No routine adjustment is needed for renal impairment.
Renal Impairment
No specific dose adjustment is generally required; atomoxetine is not renally cleared to a clinically limiting degree.
Part 9: Discontinuation
Here atomoxetine is easy. It has no discontinuation syndrome and no rebound, unlike stimulants (which can rebound within hours) and unlike the alpha-2 agonists clonidine and guanfacine (which risk rebound hypertension on abrupt stop and must be tapered).
- Physiologically, you can stop atomoxetine without a taper.
- A brief taper is still reasonable clinical courtesy (it lets you watch for return of ADHD symptoms and any mood change), but it isn't pharmacologically required.
- There is no "lose the response by stopping wrong" phenomenon here, as there is with lithium.
The clean on/off behavior is worth saying out loud to ambivalent patients: "If it doesn't suit you, we can just stop; there's no withdrawal and nothing to taper." That reassurance improves willingness to try it in the first place.
Part 10: Atomoxetine vs the Alternatives
vs Stimulants (Methylphenidate, Amphetamines)
Stimulants win on efficacy, and it isn't close: effect size 0.8–0.9 vs 0.4–0.6; NNT 2–4 vs 5–7; 56% vs 45% response in the key head-to-head. Stimulants also work in hours, not weeks. Atomoxetine's counter-advantages: not controlled, no abuse potential, once-daily coverage with no rebound, safer in substance use, and better for comorbid anxiety. Stimulants cause insomnia and appetite loss; atomoxetine causes fatigue. For most straightforward ADHD, a stimulant is the better first drug; reserve atomoxetine for the specific niches.
vs Viloxazine (Qelbree)
The other unscheduled non-stimulant NRI, and a close analog. Similar efficacy (NNT ~5–7). Viloxazine lacks the sudden-cardiac-death warning and barely notices CYP2D6, but it is a strong CYP1A2 inhibitor (several CYP1A2 substrates are contraindicated with it), its suicidality boxed warning covers adults as well as children, and it is brand-only. Both take about 4–6 weeks to work; the faster onset claimed for viloxazine rests on one pediatric trial. Atomoxetine is more studied, longer on the market, and generic. Reasonable to try one if the other disappoints.
vs Alpha-2 Agonists (Guanfacine ER/Intuniv, Clonidine ER/Kapvay)
Different mechanism entirely (alpha-2A agonism, not reuptake inhibition). Comparable-to-slightly-different effect sizes (guanfacine 0.4–0.9, clonidine 0.7–0.8). Atomoxetine is generally better tolerated and helps anxiety; the alpha-2 agonists improve sleep, reduce tics, and are safer in bipolar disorder, and guanfacine has the better evidence for augmenting a stimulant. Pick by comorbidity: tics/insomnia/bipolar → alpha-2 agonist; anxiety/substance use → atomoxetine.
vs Bupropion (Off-Label)
Bupropion is weaker for ADHD (effect size 0.3–0.5) but is the one to reach for when depression or nicotine dependence rides along. Note it's also a 2D6 inhibitor if you ever combine.
ADHD with a substance use disorder, and ADHD where a controlled substance is off the table. In those situations its modest average efficacy is outweighed by everything it doesn't do: it doesn't get abused, diverted, or require you to see the patient monthly to keep writing it.
Mechanism
Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI). By blocking the presynaptic norepinephrine transporter, it raises synaptic norepinephrine, and, because the prefrontal cortex clears dopamine largely via the NE transporter, it also raises dopamine in the frontal lobes. It does not raise dopamine in the striatum/nucleus accumbens, the reward circuitry that mediates euphoria and abuse. That single anatomical fact explains atomoxetine's entire personality: it treats the prefrontal attention/executive deficits of ADHD, but it isn't reinforcing, isn't abusable, and isn't scheduled.
Two consequences follow directly from the mechanism. First, the noradrenergic load is why atomoxetine raises HR/BP and carries a mania-induction concern; it's pharmacologically a noradrenergic antidepressant wearing an ADHD label. Second, its ~5-hour half-life through a single CYP2D6 pathway is why the 2D6 story dominates its interactions and why poor metabolizers get hit so hard. It shares its core mechanism with reboxetine, the European antidepressant, and viloxazine, its newer non-stimulant sibling.
The Bedside Cheat Sheet
Starting
- Capsules (generic). Start 40 mg/day → 80 mg/day after a minimum of 3 days; max 100 mg (adult)
- Peds: 0.5 mg/kg → target ~1.2 mg/kg (max 1.4 mg/kg or 100 mg, whichever is less)
- Once daily in the morning is fine; split BID (morning and late afternoon) for tolerability
The two rules
- Dose high enough (target ~1.2 mg/kg / 80–100 mg; 40 mg is a start, not a treatment dose)
- Wait long enough (some benefit ~2 wks; full effect up to 10 wks; judge at 4–6 wks minimum)
CYP2D6 (the one landmine)
- Poor metabolizer or on fluoxetine / paroxetine / bupropion → usual start, 4-week titration interval, usual target and maximum (label)
Monitoring
- HR + BP at baseline, every dose step, then periodically. No routine labs, ECG, or levels
- Watch suicidal ideation (kids/teens, early), and mania, psychosis and aggression in anyone (they can appear with no bipolar history)
Side effects
- GI → take with food, split dose
- Fatigue/somnolence (the characteristic one) → dose PM; insomnia → dose AM
- Raises HR/BP; rare hepatotoxicity (stop for jaundice/dark urine); urinary/sexual effects in adults
Don't forget
- Contraindicated: MAOI use (or within 14 days), narrow-angle glaucoma, pheochromocytoma, severe cardiac or vascular disease
- Avoid in bipolar disorder (mania risk); prefer guanfacine/clonidine there
- Not for depression (failed trials): consider bupropion for ADHD + depression
- No taper needed, no rebound, no withdrawal: clean to stop
- Best (not fallback) choice: ADHD + substance use, or when a controlled substance is off the table
Atomoxetine will never be the most effective ADHD drug in the room; the stimulants own that title and always will. It is the ADHD medicine you can prescribe to the patient in recovery, the patient you can't see every month, the patient who's anxious, the patient who can't or won't take a controlled substance, and the patient for whom a lethal-in-overdose or divertible drug is the wrong idea. In return it asks for two disciplines, dosing to the milligram-per-kilogram target and giving it the weeks it needs, plus a check of the med list for a CYP2D6 inhibitor before you write. Meet those conditions and it treats ADHD without a controlled substance, for the patients who need exactly that.